SELLAS Life Sciences (SLS) Net Cash Flow Growth (1y) (2011 - 2026)
SELLAS Life Sciences (SLS) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 53.46% |
| 10 | SELLAS Life Sciences | 1.90 Bn | 1.79 Bn | - | 143.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143.61% |
| Dec 31, 2025 | 484.35% |
| Sep 30, 2025 | 60.07% |
| Jun 30, 2025 | 66.55% |
| Mar 31, 2025 | -8.65% |
| Dec 31, 2024 | -396.53% |
| Sep 30, 2024 | 220.80% |
| Jun 30, 2024 | -22.03% |
| Mar 31, 2024 | 134.40% |
| Dec 31, 2023 | 65.92% |
| Sep 30, 2023 | -74.46% |
| Jun 30, 2023 | -144.07% |
| Mar 31, 2023 | 195.41% |
| Dec 31, 2022 | 14.27% |
| Sep 30, 2022 | -55.09% |
| Jun 30, 2022 | 814.81% |
| Mar 31, 2022 | 2.28% |
| Dec 31, 2021 | -118.18% |
| Sep 30, 2021 | -174.77% |
| Jun 30, 2021 | 155.31% |